Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 12.49
- Piotroski Score 8.00
- Grade Buy
- Symbol (UTHR)
- Company United Therapeutics Corporation
- Price $367.42
- Changes Percentage (0.85%)
- Change $3.09
- Day Low $361.97
- Day High $369.97
- Year High $417.82
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $360.00
- High Stock Price Target $575.00
- Low Stock Price Target $215.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $21.12
- Trailing P/E Ratio 13.02
- Forward P/E Ratio 13.02
- P/E Growth 13.02
- Net Income $984.80 M
Income Statement
Quarterly
Annual
Latest News of UTHR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Meet Savannah Guthrie's Kids! All About the 'Today' Star's Daughter Vale and Son Charley -- and How They're Following in Her Footsteps
Savannah Guthrie, host of the Today show, shares her joy of motherhood with her two children, Vale and Charley. Despite challenges with fertility, she embraces her role as a mother, witnessing her chi...
By PEOPLE.com | 1 day ago -
Savannah Guthrie's Daughter Vale, 10, Is Her Biggest Supporter as She Leaves Mom a Sweet Note on Election Day: 'You Got This'
Hannah Sacks, a Parents team writer/reporter at PEOPLE since May 2023, has contributed to various publications. Savannah Guthrie shared a sweet note from her daughter Vale on Election Day, expressing ...
By PEOPLE.com | 2 weeks ago -
SD Guthrie Berhad's (KLSE:SDG) Intrinsic Value Is Potentially 24% Below Its Share Price
The analyst price target for SD Guthrie Berhad is RM4.67, 33% above the fair value estimate. An estimation of the intrinsic value using the Discounted Cash Flow model is explained, detailing future ca...
By Yahoo! Finance | 2 weeks ago
